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Abstract
Background: Information concerning lipid disturbances in HIV-infected women on antiretroviral therapy (ART) is
scarce. The objective of the study is to describe the lipid profile in a large cohort of HIV-infected women on
contemporary ART and analyse differences between regimes and patient’s characteristics.
Methods: Observational, multicentre, cross-sectional study from the Spanish VACH Cohort. 922 women on stable
ART without lipid-lowering treatment were included.
Results: Median age was 42 years, median CD4 lymphocyte count was 544 cells/mm3, and 85.6% presented
undetectable HIV-1 viral load. Median total cholesterol (TC) was 189 mg/dL (interquartile range, IQR, 165-221), HDL
cholesterol 53 mg/dL (IQR, 44-64), LDL cholesterol 108 mg/dL (IQR, 86-134), and triglycerides 116 mg/dL (IQR, 85-163).
Mean accumulated time on ART was 116 months; 47.4% were on NNRTI-based regimes, 44.7% on PI, and 6.7% on only-
NRTI therapy. 43.8% were also hepatitis C (HCV) coinfected. Patients on PI treatment presented higher TC/HDL ratio
than those on NNRTI (p < 0.001). Significantly higher HDL values were observed in NNRTI-treated patients. HCV-
coinfected patients presented lower TC/HDL ratio than the non HCV-coinfected. In multivariate analysis, factors
independently associated with TC/HDL ratio were age, triglyceride levels and HCV co-infection. PI treatment presented
a non-significant association with higher TC/HDL ratio.
Conclusions: In HIV-infected women, the NNRTI-based ART is associated with a better lipid profile than the PI-
based. Factors unrelated to ART selection may also exert an independent, significant influence on lipids; in
particular, age, and triglyceride levels are associated with an increased TC/HDL ratio while HCV co-infection is
associated with a reduced TC/HDL ratio.
Background
The increase in cardiovascular risk (CVR) observed in
HIV-infected patients is a cause for concern. Most clini-
cal studies have detected a relationship between cardio-
vascular disease and traditional risk factors, among which
age, male gender, smoking, hypertension and diabetes are
the most important. There is far less information con-
cerning CVR in HIV-infected female patients. For years,
some inequalities in female participation in clinical stu-
dies have been observed. In HIV infection, women have
been under-represented as participants as trial partici-
pants in for all types of clinical interventions [1]. This is
in sharp contrast with the fact that more than 50% of
HIV-infected adults worldwide are women [2], and inci-
dence figures show a significant increase in the number
of newly-infected HIV infected women. Since the begin-
ning of the epidemic, the number of women diagnosed
with HIV/AIDS has risen more than 3-fold from 8% of
all cases in 1985 to 27% in 2006 [3].
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There is concern about the potential cardiovascular
complications of antiretroviral therapy (ART) in women
because of their characteristics and the limitations of
published studies. Physiological ageing and also meno-
pause increases CVR. Factors potentially involved in
determining sex differences in pharmacological effects
that may be involved in CVR include differences in body
weight and composition, pharmacokinetic issues related
to drug metabolism and other, such as nutritional factors,
concomitant treatments as well as hormonal and repro-
ductive status [4].
Lipid disturbances are frequently observed in HIV infec-
tion, and they include elevations in triglycerides (TG) and
total cholesterol (TC), and reduced levels of high-density
lipoprotein cholesterol (HDL). They may be related to
ART and also to the direct effect of HIV. Low TG and
high HDL levels have been described in HIV infected
women in comparison to men [5], but HIV-specific and
host factors may influence these differences. In studies on
women from the general population, HDL and TG are
independent predictors of CV disease-related death [6].
There are few data regarding the effect of gender on lipids
in HIV-infected patients. Therefore, the main objective of
our study is to describe the lipid profile in a contemporary
large cohort of HIV infected women on ART and analyse
differences between regimes and patient’s characteristics.
Methods
Design of the study
This is a multicentre, cross-sectional study, designed to
describe the lipid profile, CVR factors and HIV-related
variables in a cohort of HIV-infected women on ART
without lipid-lowering treatment
Study Population
Patients were included in the Spanish VACH cohort.
Characteristics of this cohort have been described else-
where [7]. In summary, the VACH cohort collects clinical
information of HIV-infected patients form 47 centres
throughout the Spanish geography. Nearly 15,000
patients, aged 16 years or older, were included in the
cohort at the time of the study. Clinical data were
recorded in a common computer database (ACyH®,
Betek 43 SL, Huelva, Spain). All patients gave their writ-
ten informed consent prior to the inclusion in the study.
Inclusion/exclusion criteria
Female subjects aged 18 years or more at the time of
enrolment with documented HIV-1 infection, attending
VACH cohort outpatient HIV-1 treatment centres for rou-
tine, scheduled, clinical appointments, were eligible for
this study. In order to be eligible, subjects must have been
on at least three antiretroviral drugs, at the time of the
study visit. Only those patients with more than three
months on the current treatment were included in the
study, and no upper limit of treatment length was set.
Being on any lipid-lowering treatment was an exclusion
criterion. Antiretroviral (ARV) naïve subjects or ARV
experienced, but currently untreated subjects or those cur-
rently treated with NRTI bi- or mono therapy were not
eligible for this study. Informed consent was obtained
from the patients at study entry data collection in the
VACH Cohort.
Data collecting and variables analysed
Data were prospectively collected according to standar-
dised criteria and are electronically stored in the ACyH®,
an application specifically developed for the management
of the cohort data. On enrolment, standardised data col-
lection electronic forms were completed at the sites pro-
viding information from physical examination, patient
interview and patient case notes, concerning family history
of coronary heart disease, patient prior history of CVD
and diabetes, cigarette smoking, blood pressure, diabetes
mellitus and anti-hypertensive therapy and fasting serum
lipid levels. Physical examination included anthropometric
determinations such as weight, height, waist and hip dia-
meters. All laboratory measurements were obtained in at
least 8 hours of fasting state at each site. Lipid variables
analysed included TC, TG and HDL; analysis were deter-
mined by enzymatical methods using standardised com-
mercial kits; LDL was calculated by Friedewald’s formula,
except in patients with levels of cholesterol over 400 mg/
dL (LDL = TC - ([TG/5] + HDL). The main variable ana-
lysed was TC/HDL ratio. This was selected because of its
proven value in predicting cardiovascular outcomes in
both genders [8]. HIV-related laboratory variables include
CD4 lymphocyte count and HIV-1 viral load. Renal func-
tion variables included creatinine plasma levels and esti-
mated glomerular filtration ration rate (eGFR), which was
calculated using the MDRD formula. The diagnosis of
hepatitis C infection (HCV) was established in the pre-
sence of antibodies to hepatitis C virus. Information was
unavailable regarding other important variables such as
viral load, fibrosis degree or whether the patient had
received specific treatment or not.
Additionally, all cumulative data characterising the
patient’s underlying HIV-1 infection since inclusion in any
of the individual cohorts were collected, including infor-
mation on demography, antiretroviral therapy, CD4 cell
counts and HIV-1 viral load. Dates of diagnosis of all
AIDS-defining diseases were recorded using the 1993 clin-
ical definition of AIDS from the Centres for Disease Con-
trol and Prevention.
Antiretroviral therapy
Most patients (98.8%) were on at least two nucleoside
reverse transcriptase inhibitors (NRTI) therapy. 48.6%
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were also receiving non-nucleoside NRTI (NNRTI) and
45.9% protease inhibitors (PI). No information regarding
specific drugs was available for analysis; in most cases,
PI were low-dose ritonavir-boosted. Four groups of dif-
ferent treatments were identified: group 1, 2 NRTI + 1
PI (47.4% of the study population), group 2, 2 NRTI + 1
NNRTI (44.7%); group 3, 3 NRTI (6.7%) and group 4,
NNRTI + PI combination therapy (1.2%). This informa-
tion is also presented in Table 1.
Statistical analysis
The quantitative variables were summarized by their
mean and standard deviation (SD) or median and inter-
quartile range (IQR: P25-P75). The t-student test was used
to compare quantitative variables between two indepen-
dent groups. The analysis of variance (ANOVA) or the
non-parametric Kruskal-Wallis test was used to compare
the metabolic parameters between the four treatment
groups. If a significant difference was found in ANOVA
or Kruskal-Wallis test, it was further evaluated by using a
Bonferroni-corrected a level of 0.05/6 = 0.0083.
The relationship between the quantitative factors and
the TC/HDL ratio was evaluated with a correlation analy-
sis. The Pearson correlation coefficient was calculated
when the two quantitative variables were normally distrib-
uted, and the non-parametric Spearman rank correlation
coefficient when the variables were not normally distribu-
ted. A multiple linear regression analysis was carried out
in order to evaluate the independent effect of each factor.
Null hypothesis was rejected by a type I error minor
than 0.05 (a < 0.05). Statistical analyses were performed
using the SPSS 15.0 statistical package.
Results
922 patients were included in the study. Their clinical
characteristics are described in Table 1. In general, the
population study was composed of young, premenopau-
sal age patients with a low-risk lipid profile and well-
controlled HIV infection. Of note, was the proportion of
HCV-coinfected patients being high (43.7%). In these
patients, the most frequent HCV genotype was 1. The
main CV risk factor was tobacco smoking in 54.8% of
the study population.
The figures 1A-D shows the comparison between the
different treatment groups and the metabolic parameters
(total cholesterol, LDL, HDL and TC/HDL ratio). Globally,
significant differences were found between the treatment
groups in all the metabolic parameters (p < 0.011 for all).
Regarding the TC/HDL ratio, (figure 1A) using the Bon-
ferroni test for multiple comparisons, only statistical dif-
ferences were detected between the PI and NNRTI groups
(p < 0.001). LDL levels in the NRTI group were signifi-
cantly lower than in PI, NNRTI and NNRTI + PI groups
(p = 0.009; p < 0.001; p < 0.001, respectively) (figure 1B).
Significant differences were also found between PI and
NNRTI + PI groups (p = 0.011). Higher HDL values were
observed in NNRTI group, and multiple comparison
between groups showed significant differences between
Table 1 Patient’s clinical characteristics
n (%)
Age* 42.1 ± 8.3
CD4 lymphocyte count (cells/mm3)** 544.5 (373.5-759.5)
CD4 nadir (cells/mm3)** 184.5 (76-275)
Undetectable HIV-1 viral load (<50 cop/mL) 789 (85.6)
Previous AIDS diagnosis 241 (26.1)
Hepatitis C (n = 812) 369 (45.7)
Genotype HCV (n = 198)
1 113 (57.1)
4 47 (23.7)
3 36 (18.2)
2 2 (1.0)
Hepatitis B (n = 150) 33 (4.3)
BMI (Kg/m2)* 23.7 (4.4)
Current smoker 505 (54.8)
Hypertension 153 (16.6)
Diabetes 24 (2.6)
Way of transmission
Sexual 570 (61.8)
Injectable drug use 299 (32.4)
Blood derivatives 14 (1.5)
Vertical transmission 7 (0.8)
Unknown 32 (3.5)
Previous CV disease 13 (1.4)
Familiar history of premature CVD 46 (5.0)
10-year CV risk (Framingham)** 2% (1-4)
Total cholesterol (mg/dL)* (n = 907) 194.2 (±45.2)
HDL cholesterol (mg/dL)* (n = 907) 54.9 (±16.3)
CT/HDL ratio* (n = 907) 3.7 (±1.1)
LDL cholesterol (mg/dL)* (n = 903) 111.8 (36.6)
Triglycerides (mg/dL)** 116 (85-163)
Patients with hyperlipidemia § 480 (52.7)
Glucose (mg/dL)* 94.7 (±24.2)
Creatinine (mg/dL)* 0.78 (±0.19)
eGFR (mL/min)* 90.3 (76.9-107.2)
Current antiretroviral therapy
NRTI + NNRTI (Group 2) 437 (47.4)
NRTI + PI (Group 1) 412 (44.7)
Only NRTI (Group 3) 62 (6.7)
NRTI + PI + NNRTI (Group 4) 11 (1.2)
Thymidine NRTI 180 (19.5)
Median time on current treatment (months)** 22 (11-36)
Accumulated time on ART (months)** 116 (71-149)
N = 922.
* Media (±standard deviation); ** Median (Interquartile range); BMI: body mass
index, eGFR, estimated glomerular filtration rate by Modification of Diet in
Renal Disease (MDRD) formula. § Hyperlipidemia: (any of the following: TC
>200, LDL > 130, TG > 200, CT/HDL ratio >4.5); PI: protease inhibitor; NRTI:
nucleoside reverse transcriptase inhibitor; NNRTI: non-nucleoside reverse
transcriptase inhibitor. ART, antiretroviral therapy.
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NRTI vs NNRTI (p = 0.001) and PI vs NNRTI (p < 0.001)
groups (figure 1C). TC levels in the NRTI group were sig-
nificantly lower than in PI, NNRTI and NNTR + PI
groups (p = 0.007; p < 0.001; p < 0.001. respectively) (fig-
ure 1D). We also found significant differences between PI
and NNRTI + PI groups (p = 0.0015).
Regarding TG levels, in the NRTI, PI, NNRTI and
NNRTI + PI groups median values and IQR were as fol-
lows (mg/dL): 126.5 (88.5-173.2), 128.5 (94.2-183.0), 103.0
(77.0-145.7) and 141.0 (104.0-201.0), respectively. Using
Kruskall-Wallis test, statistically significant differences
were found between the four treatment groups (p < 0.001
for all). Using Bonferroni test for multiple comparisons,
statistical differences were detected between PI and
NNRTI groups (p < 0.001).
Table 2 shows mean values, SD and comparisons of TC/
HDL ratio in different categories of epidemiological and
clinical factors. Diabetes diagnosis and PI-treatment was
associated with statistically significant higher TC/HDL
ratios. There were no differences on values between
patients on thymidine-NRTI vs non-thymidine NRTI.
Significantly lower TC/HDL ratios were found in patients
on NNRTI treatment and HCV-coinfected. No significant
differences on TC/HDL ratio were found between HCV
genotypes.
Pearson’s and Spearman’s correlation coefficients were
calculated to evaluate the linear relationship between
TC/HDL ratio and quantitative independent factors.
TC/HDL ratio showed a positive significant correlation
with LDL (r = 0.523; CI 95%, 0.474, 0.569, p < 0.001)
and TG levels (r = 0.487; CI 95%, 0.436, 0.535, p <
0.001). Significant but weaker correlations were also
found with age (r = 0.131; CI 95% 0.067, 0.194, p <
0.001) and BMI (r = 0.151; CI 95% 0.087, 0.214, p <
0.001). These positive correlations indicate that any
increase in these values is associated with higher levels
of TC/HDL ratio, and therefore with impaired metabolic
status. To the contrary, TC/HDL ratio showed a signifi-
cant negative correlation coefficient with the eGFR (r =
-0.068; CI 95% -0.133,-0.002, p = 0.042).
In order to evaluate the role of the different indepen-
dent factors in the TC/HDL ratio, a multiple linear
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Figure 1 A-D: Graphics illustrating the level of the parameters evaluated. The data are presented as mean ± CI 95%. * Significant
differences in relation to the PI treatment group; ** Significant differences in relation to the NRTI treatment group. ANOVA of one way, and after
Bonferroni correction, p < 0.05; PI: protease inhibitor; NNRTI: non nucleoside reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase
inhibitor; CI: confidence interval.
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regression analysis was performed. All the independent
factors that showed a significant relationship with the
TC/HDL ratio in the univariate analysis (age, BMI, tri-
glycerides, eGFR, diabetes, PI treatment, NNRTI treat-
ment and HCV coinfection) were included in the
regression analyses. Of those factors, only HCV coinfec-
tion, age and TG levels remained significantly and inde-
pendently associated with the TC/HDL ratio on
multivariate analysis. PI-treatment and BMI reached
borderline statistical significance (table 3).
The interaction between the PI treatment group and
the TG levels with the TC/HDL ratio was studied and
an interaction term was included in the linear regression
model. The quantitative TG variable was dichotomized
in two groups (TG > 200 mg/dl). The b coefficients,
adjusted for all the variables in the model described pre-
viously, for the relationships between PI treatment and
the TC/HDL ratio in the TG ≤ 200 mg/dl and TG >
200 groups were 0.21 (CI 95%: -0.08;0,49; p = 0,154)
and 0.45 (CI 95%: 0.01;0,89; p = 0.044), respectively.
The interaction term did not reach statistical signifi-
cance (p = 0.252), showing that the relationships
between variables TC/HDL ratio and PI treatment
group were not modified as a function of the TG level.
Discussion
In this study we present the lipid profile of a large
cohort of HIV-infected women on contemporary ART,
without lipid-lowering treatment. Most of the patients
had low-risk lipid profile. The main findings include the
importance of age, trygliceride levels, HCV coinfection,
type of treatment (PI vs NNRTI) and BMI on plasma
lipids.
Major guidelines for lipid management are based in
LDL concentrations [9], although other parameters such
as lipoprotein TC/HDL ratios may be better predictors
of CV disease [10]. We selected TC/HDL ratio as a
major marker of CVD risk and the primary objective of
our analysis because of the greater predictive value than
the isolated parameters [11].
Although there are no differences related to gender with
regard to the efficacy of ART, an increased proportion of
ART-associated adverse events have been described in
women. Some drug-related complications such as lactic
acidosis, anaemia, liver toxicity or nevirapine-related rash
are more common in women. In the recently published
darunavir/ritonavir-based Grace trial [12], which was
designed to enrol a high proportion of treatment-experi-
enced women, no sex differences in efficacy were found,
but the rate of treatment discontinuation was significantly
Table 3 Multivariate analysis
b coefficient CI 95% b coefficient P
Age (years) 0.009 0.001;0.017 0.045
BMI (kg/m2) 0.016 -0.0001;0.032 0.052
Triglycerides (mg/dl) 0.006 0.005;0.007 <0.001
eGFR -0.002 -0.005;0.001 0.279
Diabetes 0.064 -0.345;0.473 0.757
PI treatment 0.261 0.000;0.522 0.050
NNRTI treatment 0.046 -0.214;0.306 0.728
HCV coinfection -0.217 -0.355;-0.079 0.002
Factors independently related to TC/HDL ratio (N = 785).
BMI: body mass index; eGFR, estimated glomerular filtration rate by
Modification of Diet in Renal Disease (MDRD) formula; CI: confidence interval;
PI: protease inhibitor; NNRTI: non nucleoside reverse transcriptase inhibitor;
HCV: hepatitis C virus.
Table 2 Univariate analysis of clinical and
epidemiological factors and TC/HDL ratio
n TC/HDL ratio (mean ± SD) p
Previous AIDS
Yes 230 3.85 ± 1.12 0.165
No 677 3.71 ± 1.11
HIV-1 viral load
Detectable 131 3.89 ± 1.20 0.099
Undetectable 776 3.72 ± 1.10
Hypertension
Yes 149 3.87 ± 1.26 0.156
No 758 3.72 ± 1.09
Previous CVD
Yes 13 3.76 ± 1.42 0.958
No 894 3.74 ± 1.12
Diabetes
Yes 23 4.43 ± 1.59 0.003
No 894 3.73 ± 1.10
Type of smoker
Current smoker 496 3.79 ± 1.18 0.193
Ex-smoker 61 3.88 ± 1.36
Never smoker 350 3.67 ± 0.97
T-NRTI treatment
Yes 178 3.68 ± 1.03 0.414
No 729 3.76 ± 1.13
PI treatment
Yes 417 3.94 ± 1.23 <0.001
No 490 3.58 ± 0.98
NNRTI treatment
Yes 440 3.58 ± 0.97 <0.001
No 467 3.91 ± 1.23
HBV coinfection
Positive 31 3.88 ± 1.25 0.462
Negative 728 3.73 ± 1.11
HCV coinfection
Positive 360 3.63 ± 1.15 0.034
Negative 438 3.80 ± 1.08
SD: Standard deviation; AIDS: Acquired immune deficiency syndrome; Previous
CVD: previous history of cardiovascular disease: T-NRTI: Thymidine NRTI (AZT
or d4T); PI: protease inhibitor; NNRTI: non-nucleoside reverse transcriptase
inhibitor; HBV: hepatitis B virus; HCV: hepatitis C virus.
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higher in women (32.8%) compared with men (23.2%).
The primary reasons for study discontinuation were loss
to follow up and adverse effects (AE); however, no trends
toward a specific type of AE driving discontinuations in
either group were found.
Information about dyslipidaemia in HIV-infected
women on ART is scarce. This may be due to the
reduced number of women included in clinical studies or
to the fact that they have not assessed gender as an inde-
pendent variable. A small observational study published
in 2001 described that metabolic adverse effects during
ART were more pronounced in women than in men [13].
To the contrary, Richter et al [14] described older age,
white race, PI use and male sex as significant factors
associated with dyslipidaemia. HIV-related fat distribu-
tion abnormalities, commonly associated with lipid dis-
turbances, have been described in the past as more
frequent in women [15]. Our results are similar to those
of Anastos et al [16], who presented the largest series of
patients treated women to date; they found a dyslipidae-
mic pattern only in HIV-infected female patients on PI-
containing therapy.
It is well known that increased age is related to a pro-
atherogenic lipidic profile. In fact, several cross-sectional
population studies have demonstrated that TC and LDL
levels increase after the onset of puberty until 50 years of
age, and then plateau until 70 years of age [17]. In addi-
tion, in women HDL levels decrease with age [18], and
the transition from pre-menopause to post-menopause is
associated with reduction in HDL and increase in the
levels of LDL, TG, Lp (a), which are independent CV risk
factors [19].
Our data on the effect of HCV infection on lipid metabo-
lism are consistent with previous studies, which describe
lower lipoprotein levels (TC, LDL and HDL) in HCV
mono-infected patients in comparison with control sub-
jects [20]. HCV infection is associated with enhanced lipo-
genesis, reduced secretion, and beta-oxidation of lipids
[21]. This described finding is more pronounced in patients
infected with HCV genotype 3a [22]. In HIV/HCV coin-
fected patients, low TC levels have been reported, indepen-
dently of the use of PI or NNRTI. In a study of high-risk
for insulin resistance (IR) in hispanic men HIV/HCV co-in-
fected patients [23], HCV mitigated the elevation of trigly-
cerides associated with ART and modified the relationships
between TG, IR and HDL. In our study population, 43% of
the patients were also HCV coinfected and we found it to
be an independent factor associated to lower TC/HDL
ratio. However, despite a favourable lipid profile, HCV
infection is associated with a higher risk of coronary artery
disease after adjusting for traditional risk factors [24]. A
recently published systematic review [25] has found a high
likelihood of having carotid atherosclerosis in HCV-mono-
infected patients. The reasons for this discrepancy are not
well understood. Moreover, systemic inflammation, which
plays a significant role in development and atherosclerosis
progression, is not significantly different in HCV-positive
and HCV-negative patients [26]. HCV viral particles have
been detected in atheromatous plaques [27], suggesting
HCV could play a role in carotid atherosclerosis through
local action. Some HCV proteins can cause oxidative stress
with increased local reactive oxygen species [28], support-
ing the hypothesis that HCV could potentiate the oxidation
of lipoprotein. An increased oxidant stress has been
described in HIV-infected women [29]. A significant asso-
ciation was found between levels of oxidant stress as mea-
sured by plasma F2-isoprostane concentrations and HCV
viremia, transaminase level, waist circumference and
homocysteine levels. Therefore, in this case a favourable
lipid profile should not be construed as a protection against
atherosclerosis.
It has long been known that ART has a significant
effect on plasma lipids [30]. Normalization in lipid values
is usually observed in naïve patients after beginning ART
and in general, a rise in TC, TG and LDL is observed in
patients on stable ART. A pro-atherogenic lipid profile,
with increased number of small LDL particles and a
reduced number of small HDL particles has been
described in a large study of female HIV-patients on
ART [31]. There is a wide range variation in the elevation
in lipids levels in HIV infected patients that may be influ-
enced by multiple factors [32]. In general, the use of PI/r
is associated with higher elevations in TC and TG than
with the use of NNRTI. There is no clear information
about the influence of gender in these lipid derange-
ments. We have shown that in HIV infected women on
ART, the use of PI or NNRTI is associated with an oppo-
site effect on TC/HDL ratio, and NNRTI use is asso-
ciated with a better lipid profile. In univariant analysis,
the use of NNRTI is associated with a reduced TC/HDL
ratio when compared to PI. In multivariable analysis a
borderline effect of PI on TC/HDL ratio is observed, sug-
gesting a partially unrelated to ART pathogenesis of lipid
changes in HIV-infected women. This beneficial effect on
the lipids of the NNRTI may have clinical relevancy, pro-
vided that the antiretroviral treatment has to be kept
indefinitely and considering the fact that aging associates
with an increase of cardiovascular risk.
The use of thymidine-NRTI therapy (d4T or AZT) has
been displaced from the first line of treatment for most
of the HIV-treatment guidelines because of side effects.
The prolonged use of these drugs has been convincingly
associated with alterations in body fat distribution and
metabolic derangements, such as insulin resistance or
hypertriglyceridaemia. In naive patients, comparing sta-
vudine to tenofovir (TDF) (plus lamivudine and efavirenz
in both arms), stavudine led to significantly greater
increases in TG and TC at 96 weeks than TDF [33]. Also,
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in the 934 study, AZT led to significant greater increases
in TC than TDF at 96 weeks, without significant differ-
ences in LDL, HDL or TG values [34]. Also, when
t-NRTI are switched to TDF or abacavir, TC and TG
values are improved [35]. However, we could not find a
significant association of t-NRTI on TC/HDL ratio; it is
still only speculation that women could in part be pro-
tected from lipid derangements associated with the use
of t-NRTI.
Our study has several limitations: no information is avail-
able regarding HCV viral load or specific HCV treatment.
The selection of patients without lipid lowering treatment
may bias our study population to a lipid-disturbances pro-
tected group of patients. We considered that the inclusion
of patients with lipid lowering treatment while on ART
adds confusion when interpreting lipid profile. Pharmaco-
logic interactions between statins or fibrates with ARV
drugs and different dosages of drugs may render heteroge-
neous results on lipids that are difficult to analyse. Absence
of detailed information about specific drugs is also a limita-
tion of the study. On the other hand, it has the strength to
have a high number of patients studied.
Conclusions
In summary, we have shown that in HIV infected women,
NNRTI-based ART is associated with a better lipid profile
than the PI-based. The beneficial effect on lipids of
NNRTI should make their use advisable in patients with
increased cardiovascular risk, such as older women. Age
and TG levels are independent factors significantly asso-
ciated with increased TC/HDL ratio and HCV coinfection
is independently associated with a reduced TC/HDL ratio.
These factors must be taken into account when analysing
the effect on lipid profile of different types of ART.
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